Clin2
NCT07596381Possibly a fitNot yet recruiting

Testing a new FAK inhibitor for advanced solid tumors

Advanced Solid Tumors

Part of Cancer clinical trials.

This study tests whether a new drug called a FAK inhibitor can help patients with advanced cancers that have spread or stopped responding to standard treatments. FAK is a protein that helps cancer cells grow, and blocking it may slow tumor growth.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
75 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have a confirmed diagnosis of advanced or metastatic solid tumor (cancer that has spread) and standard treatments have failed, aren't available, or you couldn't tolerate them
  • You are between 18 and 75 years old
  • You have at least one measurable tumor lesion that can be tracked on imaging scans
  • You have a good functional status (able to do light activities; ECOG score 0 or 1)
  • Your organs are working adequately, and you are expected to live at least 3 months
  • You can take medications by mouth and have not had major stomach or intestinal surgery

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06314373Recruiting· Phase 1/Phase 2
Study of a new drug for advanced solid tumors

This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.

Shanghai, Shanghai Municipality
NCT06832982Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.

Beijing, Beijing Municipality
NCT06694480Recruiting· Phase 1
Study of FID-022 for advanced solid tumors

This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.

Los Angeles, California
NCT06736327Recruiting· Phase 1
Testing a new drug, SKB500, for advanced solid tumors

This trial tests a new drug called SKB500 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and may help shrink tumors.

Jilin City
NCT06990698Recruiting· Phase 1
Testing FP008 in advanced solid tumors

This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.

Wuhan, Hubei
NCT06718621Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.

Shanghai, Shanghai Municipality

Hear when a new Advanced Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.